1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Royalty Pharma plc

Royalty Pharma plc

RPRX
Royalty Pharma plcUS flagNASDAQ
58.29
USD
+0.64
- -
25.84BMarket Cap

Total Valuation

Royalty Pharma plc carries a market capitalization of 25.84B, placing it among publicly traded companies globally. Its enterprise value stands at 35.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap25.84B
Enterprise Value35.18B

Share Statistics

Royalty Pharma plc currently has 445.75M shares outstanding.

Shares Outstanding445.75M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Royalty Pharma plc trades at a trailing price-to-earnings ratio of 30.05. The price-to-sales ratio is 9.66, and the price-to-book ratio stands at 3.66.

PE Ratio30.05
PS Ratio9.66
PB Ratio3.66
P/TBV Ratio4.23
P/FCF Ratio10.50
P/OCF Ratio8.23

Enterprise Valuation

On an enterprise value basis, Royalty Pharma plc trades at an EV/EBITDA multiple of 22.18 and an EV/FCF ratio of 10.54. The EV/Sales ratio of 13.87 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.25 provides insight into valuation relative to core operating earnings.

EV / Sales13.87
EV / EBITDA22.18
EV / EBIT22.25
EV / FCF10.54

Financial Position

Royalty Pharma plc maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.58, indicating elevated leverage, while an interest coverage ratio of 4.39 demonstrates adequate ability to service its debt obligations.

Current Ratio2.80
Quick Ratio2.79
Debt / Equity91.58
Debt / EBITDA5.65
Interest Coverage4.39

Financial Efficiency

Royalty Pharma plc posts a return on equity of 12.37 and a return on invested capital of 8.72.

Return on Equity (ROE)12.37
Return on Assets (ROA)4.27
Return on Invested Capital (ROIC)8.72
Return on Capital Employed (ROCE)3.54
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Stock Price Statistics

Royalty Pharma plc's stock has gained approximately 62.95779% over the past 52 weeks. The 50-day moving average sits at 59.42, while the 200-day moving average is 50.40.

Beta (5Y)N/A
52-Week Price Change62.95779%
50-Day Moving Average59.42
200-Day Moving Average50.40
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Royalty Pharma plc generated 2.54B in revenue and converted that into 815.00M in net income, yielding earnings per share of 2.42. EBITDA reached 1.59B, while operating income came in at 1.58B.

Revenue2.54B
Gross ProfitN/A
Operating Income1.58B
Pretax Income1.35B
Net Income815.00M
EBITDA1.59B
EBIT1.58B
Earnings Per Share (EPS)2.42

Balance Sheet

Royalty Pharma plc holds 1.73B in cash and equivalents against 8.96B in total debt, resulting in a net debt position of 8.15B. Total book value stands at 6.83B, with working capital of 1.13B providing operational flexibility.

Cash & Cash Equivalents1.73B
Total Debt8.96B
Net Debt8.15B
Equity (Book Value)6.83B
Book Value Per Share15.33
Working Capital1.13B

Cash Flow

Royalty Pharma plc produced 2.98B in operating cash flow over the past twelve months.

Operating Cash Flow2.98B
Capital ExpendituresN/A
Free Cash Flow2.98B
FCF Per Share6.81

Margins

Royalty Pharma plc operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 62.35 and net profit margin of 32.14 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin62.35
Pretax Margin53.23
Profit Margin32.14
EBITDA Margin62.54

Dividends & Yields

The company's payout ratio of 21.17 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.91
Dividend YieldN/A
Payout Ratio21.17
Shareholder Yield1.13
FCF Yield9.52

Scores

Royalty Pharma plc posts an Altman Z-Score of 2.16, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.16